CEPI Awards $5 Million to Nagasaki University for AI-Powered Nanoball mRNA Vaccine Platform Against Disease X
核心洞察
The Coalition for Epidemic Preparedness Innovations (搜索) (CEPI) has awarded up to $5 million to Nagasaki University to develop a novel "nanoball" mRNA (搜索) vaccine platform that encases mRNA in negatively-charged nano-sized particles for enhanced stability and delivery.
The technology will be tested against severe fever with thrombocytopenia syndrome virus (搜索) (SFTSV (搜索)), a tick-borne pathogen threatening East Asia, with AI-powered antigen design from NEC OncoImmunity (搜索) to optimize vaccine targets.
The nanoball platform offers significant advantages including freeze-drying capability, room temperature storage, and potential rapid adaptation to combat future pandemic threats including hypothetical "Disease X (搜索)."
The Coalition for Epidemic Preparedness Innovations (搜索) (CEPI) has committed up to $5 million in funding to support groundbreaking research at Nagasaki University in Japan, where scientists have developed a revolutionary "nanoball" mRNA (搜索) vaccine platform designed to combat emerging infectious diseases with pandemic potential. This next-generation technology represents a significant advancement in vaccine delivery systems, offering enhanced stability and broader accessibility compared to conventional lipid nanoparticles (搜索).
Novel Nanoball Technology Addresses Key Vaccine Challenges
The pioneering nanoball platform developed by researchers at Nagasaki University encases messenger RNA (mRNA (搜索)) in nano-sized, negatively-charged particles composed of polyglutamic acid (搜索). Despite both the nanoball surface and cell membrane possessing negative charges—typically causing repulsion—the technology's nanoscale design and surface chemistry enable efficient cellular uptake through endocytosis pathways.
Professor Kouichi Morita, Dean and Program Coordinator at Nagasaki University's Institute of Tropical Medicine, explains that the polyglutamic acid (搜索)-based coating plays a critical role in stabilizing internal mRNA (搜索) by physically shielding it from enzymatic degradation and environmental stresses. This protection significantly enhances payload stability during storage and after administration, particularly important for deployment in regions with limited cold-chain logistics.
The technology demonstrates several advantages over widely used lipid nanoparticles (搜索) (LNPs), including superior physical and chemical stability, enhanced cellular uptake despite negative surface charge, and improved storage characteristics with potential for longer shelf life and higher thermal tolerance.
AI-Powered Vaccine Design Targets SFTS Virus
The CEPI-funded research will focus on developing an AI-enabled nanoball mRNA vaccine (搜索) to protect against severe fever with thrombocytopenia syndrome virus (搜索) (SFTSV (搜索)), an emerging tick-borne pathogen from the Phenuivirus family that poses a serious public health threat in Japan and wider East Asia. The disease disproportionately affects high-risk populations including farmers, forestry workers, and others with occupational exposure to woodland and rural environments.
NEC OncoImmunity (搜索) (NOI) will contribute proprietary AI algorithms to identify highly conserved and immunodominant epitopes (搜索) for vaccine inclusion. Dr. Saverio Niccolini, CEO of NEC OncoImmunity, notes that their AI models can identify precise pathogen regions that lead to efficient protection, allowing for vaccine designs associated with higher efficacy.
"Our tools can identify the precise regions of the pathogen that will lead to efficient protection," Niccolini explains. "Furthermore, the precise knowledge permitted by AI can allow us to generate vaccine designs associated with higher efficacy."
Enhanced Storage and Global Accessibility
A key breakthrough of the nanoball technology lies in its ability to be freeze-dried and stored for extended periods at either refrigerator or room temperature. This capability eliminates the need for complex cold-chain requirements that have historically limited vaccine distribution in low- and middle-income countries.
Professor Morita emphasizes that for low- and middle-income countries, these features could be transformative through improved storage and distribution by reducing dependence on ultra-cold storage infrastructure, lower manufacturing costs due to potential dose-sparing effects and simplified formulation processes, and enhanced vaccine equity by enabling faster, more localized production and deployment during outbreaks.
Supporting the 100 Days Mission
The research aligns with CEPI's ambitious 100 Days Mission, which aims to develop vaccines against new viruses with outbreak potential in as little as three months. Mitsusaka Kitano, Project Leader at CEPI, explains that mRNA (搜索) technology has been identified as a pivotal enabler of this mission due to its flexibility as a rapid-response platform.
"If the world had delivered a vaccine in 100 days from the time when the COVID-19 (搜索) viral sequences were released, a vaccine would have become available in April 2020, when there were cumulatively just over 2 million cases of COVID worldwide, rather than in December 2020, when there were almost 70 million," Kitano notes.
Platform Adaptability for Future Threats
Beyond SFTS, the nanoball platform is designed for rapid adaptation to develop vaccine candidates against other pathogens, including novel or as-yet-identified "Disease X (搜索)" that could cause serious epidemics or pandemics. Professor Morita indicates that successful development of the SFTS vaccine would serve as critical proof-of-concept for rapidly creating vaccines against future epidemic or pandemic threats.
The platform's modular design supports rapid adaptation to new pathogens, while its simplified formulation and potential for technology transfer can accelerate local production in low- and middle-income countries and support decentralized manufacturing during future outbreaks.
Strategic Independence and Global Impact
The nanoball delivery system offers strategic advantages by being distinct from conventional lipid nanoparticle technologies, potentially enabling greater freedom to operate and reducing legal and licensing barriers, particularly for public or academic institutions and manufacturers in the Global South.
This innovation represents a convergence of cutting-edge science and practical public health needs, potentially transforming how the world responds to emerging infectious disease threats while ensuring equitable access to life-saving vaccines across all economic settings.